KPI Therapeutics Announces Expanded Drug Programs In Eye And Skin Diseases

SEATTLE--(BUSINESS WIRE)--KPI Therapeutics, a clinical-stage biotechnology company, today announced it initiated two new research programs to treat such diseases as Atopic Dermatitis, Dry Eye Syndrome, and Uveitis at the BIO CEO & Investment Conference in New York. Using novel peptides from the same family as its lead autoimmune drug dalazatide, KPI will develop topical biologic Kv1.3 inhibitors that target the immune cells which cause these autoimmune diseases. KPI is also currently conducting research in lupus and chronic pain. Dalazatide, another peptide from the ShK platform, is being developed for lupus and other autoimmune diseases.